171268-84-1

Basic information

• Product Name: 3'-O-(t-Butyldimethylsilyl)-2'-O-methyluridine
• Synonyms: 3'-O-(t-Butyldimethylsilyl)-2'-O-methyluridine
• CAS NO: 171268-84-1
• Molecular Weight: 372.494
• Mol File: 171268-84-1.mol
• Article Data: 7

Chemical Properties

• Density: 1.20±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 3'-O-(t-Butyldimethylsilyl)-2'-O-methyluridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-O-(t-Butyldimethylsilyl)-2'-O-methyluridine(171268-84-1)
• EPA Substance Registry System: 3'-O-(t-Butyldimethylsilyl)-2'-O-methyluridine(171268-84-1)

Safety Data

• Hazardous Substances Data: 171268-84-1(Hazardous Substances Data)

Usage

General Description

3'-O-(t-Butyldimethylsilyl)-2'-O-methyluridine is a chemical compound that belongs to the class of uridine derivatives. It is a modified form of uridine, in which a t-Butyldimethylsilyl group is attached at the 3' position and a methyl group is attached at the 2' position. This modification is often used in the synthesis of nucleoside analogs and RNA oligonucleotides for various biological and biochemical studies. The t-Butyldimethylsilyl group is used to protect the 3' hydroxyl group from undesired reactions, while the 2'-O-methyl group can enhance the stability and binding affinity of the compound to its target. 3'-O-(t-Butyldimethylsilyl)-2'-O-methyluridine is important in the field of nucleic acid research and drug development.

Upstream product

• 171268-85-2 C₃₇H₄₆N₂O₈Si 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 103285-22-9 5'-O-(4,4'-dimethoxytrityl)-2'-O-methyluridine 
• 1134031-93-8 N³-benzyloxymethyl-2'-O-methyl-3'-O-tert-butyldimethylsilyluridine 
• 367511-37-3 C₂₂H₄₂N₂O₆Si₂ 
• 2140-76-3 2'-O-methyluridine 

Downstream Products

• 1134031-93-8 N³-benzyloxymethyl-2'-O-methyl-3'-O-tert-butyldimethylsilyluridine 
• 1134032-00-0 C₄₂H₅₀Cl₄N₂O₁₆Si 
• 1134031-97-2 C₄₂H₅₀Cl₄N₂O₁₆Si 

Relevant articles and documents

Synthesis of a novel cyclopropyl phosphonate nucleotide as a phosphate mimic

The inherentin vivoinstability of oligonucleotides presents one of many challenges in the development of RNAi-based therapeutics. Chemical modification to the 5′-terminus serves as an existing paradigm which can make phosphorylated antisense strands less prone to degradation by endogenous enzymes. It has been recently shown that installation of 5′-cyclopropyl phosphonate on the terminus of an oligonucleotide results in greater knockdown of a targeted protein when compared to its unmodified phosphate derivative. In this paper we report the synthesis of a 5′-modified uridine.

S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS

Various embodiments provide STOPS? polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS? modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS? modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.

Can Phosphate-Branched RNA Persist under Physiological Conditions?

A 2′-O-methyl-RNA oligonucleotide containing a single free 2′-OH group flanking a branching phosphotriester linkage was prepared as a model for phosphate-branched RNA by using an orthogonally protected dimeric phosphoramidite building block in solid-phase